contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  createdAt
  changedAt
  isPremium
  authors {
    __typename
    name
    pageUrl
    id
  }
  companies {
    name
    id
  }
  tags {
    name
    id
  }
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
      researchContentUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


aiforia-technologies-plc-share-subscriptions-based-on-stock-options-2016a

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

changedAt

Aiforia Technologies equips pathologists and researchers in preclinical and clinical laboratories with software to translate images into discoveries, decisions and diagnoses. The company's products and services are used for medical image analysis, across a variety of fields such as oncology and neuroscience. Aiforia Technologies is headquartered in Finland.

Thank you Antti and Nora for the great answer; I received some new information, and Aiforia’s business gained even more wind in its sails in my books  Are there any coffee chats or opportunities to catch up with the CEO coming up this spring or early summer, like there were last November? Since Aiforia only reports semi-annually, it would be nice to hear an update, as quite a few things have happened in the meantime. @Antti_Luiro @Antti_Siltanen

I put your question to our AI as a test, and it gave a good answer (it relies on our extensive report and comments, so it’s not basic AI slop)  Inderesin Nora AI  Aiforia Create is a central part of the company’s strategy, and it is specifically the “toolbox” that allows users to build AI models themselves without programming knowledge. Here is a summary of Create’s business model and potential based on Inderes’ analysis and the company’s releases: 1. What is Aiforia Create and where do the “thousands of models” come from? Aiforia Create is a cloud-based platform where pathologists and researchers can annotate (mark) sample images and teach the AI to identify specific biomarkers or cell structures.  Why thousands of models? This number reflects Create’s wide use, especially in preclinical research (universities, drug development). Researchers around the world are building very specific models for very narrow research topics (e.g., a specific protein in a mouse brain or malaria identification). Every new research question or biomarker often requires its own model. Therefore, the number grows rapidly, even though not all models end up in broad clinical use.  2. Business Model: SaaS + Volume Aiforia’s business model is based on recurring billing, which typically consists of two parts:  Platform License (SaaS): The customer pays for the right to use Create or other solutions (fixed annual fee). Usage-based fee (Volume): The revenue stream is tied to the number of samples analyzed.  3. “3rd party ecosystem” and clinical potential You were right: there is a strong ecosystem element in Create.  LDT (Laboratory Developed Test): Clinical laboratories (like the Italian La Fontana yesterday) can use Create to develop their own AI models and validate them for their own clinical use (so-called LDT tests). Potential: Aiforia does not need to develop and seek expensive regulatory approvals (such as CE-IVD or FDA) for every possible indication itself. Create provides tools to partners who do the work locally. Aiforia receives scalable income from this via platform usage and sample volumes. Strategic Role: While Aiforia has its own ready-made “Clinical Solutions” models (e.g., for breast and prostate cancer), Create allows the company’s platform to spread into laboratory workflows even through diagnostic needs for which there is no ready commercial product yet.  4. Italian laboratory example (La Fontana) Yesterday’s release about the Italian laboratory is a good example of this:  Even a small laboratory can use Create to “digitize” and AI-assist its own diagnostic process (in this case, cervical cancer screening). Although an individual contract is, according to Inderes’ estimate, moderate in size, it is an important opening in the Italian market and demonstrates how Create enables the expansion of clinical use.  Summary: Create’s potential lies in making Aiforia the “Windows of AI” for pathologists – a platform on which others build their applications, and Aiforia collects revenue based on the utilization rate. Sources: Inderes’ extensive report 2025 and analyst comment April 24, 2026.  In addition to this, Aiforia can also take a model developed by its customer into its own product portfolio and gain benefits for the entire customer base:  Licensing a model developed by a partner (Case Mayo Clinic) Mayo Clinic is Aiforia’s strategic partner, and they have used Aiforia Create to develop their own AI models.  How does it work? Mayo Clinic developed and validated a colorectal cancer prognosis model (CRC) that can predict the risk of cancer recurrence based on sample images. Commercialization: Mayo Clinic has licensed this model it developed to Aiforia. This means that Aiforia can now sell this world-class expertise developed by Mayo Clinic to its other customers around the world as part of its “Clinical Solutions” range. Benefit: Aiforia gets a finished product with a world-class brand for sale, and Mayo Clinic likely receives royalty payments fro

I haven’t quite grasped Create’s business model, and therefore its potential. Yesterday’s announcement concerns a project for a fairly small lab, meaning Create enables even a small firm like that to potentially develop a clinical application for high-volume indications? Is there so-called 3rd party ecosystem potential here, where partners build applications and Aiforia receives some volume-based platform license fee? The most confusing thing when I looked at Create on Aiforia’s website is this: “Thousands of AI models have been developed with Aiforia® Create for research and clinical use cases; applications ranging from cancer research to neuroscience and even outside the medical field.” That’s an insane amount—so what exactly is this Create about? If anyone understands, please share

Here are Siltanen’s comments on Aiforia’s recent contract.  Aiforia announced on Thursday that it has signed a cooperation agreement with the Italian Laboratorio di Analisi La Fontana for AI-assisted digital pathology. The release continues the company’s series of positive steps in the European market. The individual contract is likely modest in size, so it has no impact on our forecasts.                   Inderes – 24 Apr 26              Aiforialle sopimus italialaisen laboratorion kanssa - Inderes    Uusi sopimus tuo tekoälyn aluksi kohdunkaulan syövän diagnostiikkaan.

This isn’t just “another new model,” but rather indicates that the suitability of Aiforia’s tools is being tested in new areas. Phrases like “any image analysis application” and “high-volume diagnostics” could refer to Pap smears, which would imply significant volumes, as this also involves population screening—specifically, cervical cancer screening. Screening is shifting toward testing for the cancer-predisposing papillomavirus (HPV), but Pap samples are still taken in large quantities. A standard histology slide is simpler compared to the thick cytology mass of cells, blood, and mucus that constitutes a Pap sample, so it remains to be seen what Create is capable of. It cannot detect the viral genome, but it should be able to identify cellular changes caused by the virus, especially if a specific stain is developed for them. If it works, it would represent a truly significant scaling.

It is indeed a bit curious. “La Fontana aims to develop deep learning AI models for identifying cervical cancer by utilizing Aiforia’s unique AI model development platform, Aiforia® Create.” But on the other hand: “The AI models will be implemented in the laboratory’s clinical workflow. The goal is to also deploy other AI applications related to women’s health.” “In this way, we ensure that we can provide faster and higher-quality diagnostics to more patients” I don’t know exactly how the permits and approvals work, but could it be that they first develop the model and then deploy it? The commercial significance is likely small, at least for now, but this is indeed very good news for the development of Aiforia’s algorithms and models. Of course, it is always good news that Aiforia specifically was chosen instead of other platforms. It strengthens Aiforia’s leadership in the field and provides good references. E: “The goal is to also deploy other AI applications related to women’s health.” This could refer to Aiforia’s breast cancer model, at least.

I think this announcement was a bit unclear. They are only just developing the model, and wouldn’t its implementation in clinical patient work still require a separate permit? If no permit exists for this yet, the commercial significance is minor.

Aiforia Technologies

Aiforia Technologies Plc, Company release, 24 April 2026, 11:00 a.m. EESTAiforia Technologies Plc: Share subscriptions based on stock options 2016A A total of 95,000 Aiforia Technologies Plc...

Aiforia Technologies Plc, Company release, 24 April 2026, 11:00 a.m. EESTAiforia Technologies Plc: Share subscriptions based on stock options 2016A A total of 95,000 Aiforia Technologies Plc’s new shares has been subscribed for with the stock options 2016A. For subscriptions made with the stock options 2016A and the entire subscription price of EUR 1,900.00 will be entered in the reserve for invested unrestricted equity.After entering the Trade Register, the total number of shares is 33,786,604.The new shares subscribed for under the stock options 2016A have been registered in the Trade Register on 24 April 2026, as of which date the new shares will establish shareholder rights.The shares will be traded in the Nasdaq Helsinki Plc’s First North Growth Market Finland -marketplace as an additional lot with the company’s old shares as of 27 April 2026.The terms and conditions of stock options programs are available on the company's website at <a href="https://www.aiforia.com/">https://www.aiforia.com/</a>.Further inquiries&nbsp;&nbsp; Antti Ojala, CFO, Aiforia Technologies Plc, tel. +358 40 7202448 <a href="https://investors.aiforia.com/">https://investors.aiforia.com</a>&nbsp;Certified Adviser&nbsp; UB Corporate Finance Ltd <a href="mailto:ubcf@unitedbankers.fi">ubcf@unitedbankers.fi</a>About Aiforia&nbsp;Aiforia is a trusted provider of deep learning artificial intelligence (AI) solutions for pathology. Aiforia delivers advanced software solutions that elevate diagnostic capabilities in image analysis, empowering remarkable medical discoveries both today and in the future. With thousands of AI models developed for research use and several diagnostic solutions deployed, Aiforia is making a significant impact on pathology and healthcare. In Europe, Aiforia is the leading provider of CE-IVD marked AI-powered solutions for digital pathology.&nbsp;Founded in 2013, Aiforia is a publicly traded company with a global presence and thousands of users worldwide. Headquartered in Helsinki, Finland, the company also operates subsidiaries in the United States and France, and maintains a network of local representatives across Europe and North America. Aiforia’s diverse team includes experienced AI and software developers, pathologists, medical scientists, and a dedicated commercial team. Together, they are transforming pathology through AI, enabling better care for every patient.&nbsp;Find out more at <a href="http://aiforia.com">www.aiforia.com</a>